ERBB2 and breast carcinoma: Overall, this is the first pooled analysis to demonstrate the OS and PFS benefits of CDK4/6 inhibitors in elderly patients (age ≥65 years) with advanced HR+/HER-2 metastatic or advanced breast cancer.